Press Release
"Create the new trends together, reach the new medicine world" Angel pharmaceuticals R&D center officially launched!
Angel pharmaceuticals, 15days before 15
"Create the new trends together, reach the new medicine world." On the morning of July 22, the opening ceremony of Angel pharmaceuticals R&D center was held in Zhejiang Future technology Institute (Jiaxing).
Angel Pharmaceuticals is a newly established innovative pharmaceutical enterprise. In October 2020, Angel Pharmaceutical Co., Ltd. completed the round A financing of RMB 280 million, which was jointly invested by Betta fund, Hisun Pharmaceutical, Tigermed and Puissance Capital Management, and established a strategic cooperation with Corvus Pharmaceuticals (NASDAQ: CRVS), a leading enterprise of tumor targeted immunotherapy in the United States, and successfully landed in Jiaxing Science and Technology Zone. With the mission of benefiting Chinese patients, Angel pharmaceuticals is committed to let the cancer and autoimmune diseases and the other serious diseases patients in China using the world's leading innovative medicine.
Angel Pharmaceuticals has three clinical stage pipeline drug rights in Greater China region and global patent rights for new generation BTK inhibitors, including CPI-006 for humanized monoclonal antibody against CD73, CPI-818 for ITK inhibitor target, CPI-444 for adenosine A2A portable antagonist target, and BTK inhibitor for B-cell lymphoma and autoimmune diseases.
With the strong support of Nanhu District, Jiaxing Science and Technology Zone and all shareholders, Angel pharmaceuticals R&D center has been Launched. Leaders and guests were invited to attend the ceremony.
Mr. Shao Panfeng, deputy secretary and chief of Nanhu District Committee and director of Jiaxing Science and Technology City Management Committee
The guests present were: Mr. Shao Panfeng, deputy secretary and chief of Nanhu District Committee of Jiaxing and director of Jiaxing Science and Technology Zone Management Committee, Mr. Qiu Feizhang, former deputy secretary of the Party group and deputy director of the provincial Science and Technology Department, executive vice president of Zhejiang Venture Capital Association, Mr. Shen Jinhua, deputy director of Nanhu District, etc. At the same time, the representatives of Betta fund, Tigermed, Hisun Pharmaceutical and Puissance Capital Management, the shareholders of Angel Pharmaceuticals came to the scene, and many entrepreneurs and investors also came to the scene. The whole activity was presided over by Dr. Charles Li, vice president of Angel Pharmaceuticals.
Dr. Ted Wang, General Manager of Angel Pharmaceuticals
Professor Richard Miller, CEO & Chairman of Angel Pharmaceuticals
Dr. Ted Wang, general manager of Angel pharmaceuticals, Professor Richard Miller, chairman and CEO, as well as employees of Angel pharmaceuticals USA, including team members of its partner Corvus, participated the meeting online.
Cao Xiaochun, Co-founder and General Manager of Tigermed
Ms. Cao Xiaochun, the co-founder and general manager of Tigermed, said that Angel Pharmaceuticals and Tigermed will further deepen the cooperation and work together to accelerate the listing of high-quality new drugs with clinical value and meeting clinical needs, so as to benefit more patients and allow the cooperation between two companies to yield fruitful results in innovation.
During the event, Angel Pharmaceuticals signed strategic cooperation agreements with Tigermed and Guanhe Pharmaceuticals respectively.
It was a great honor to invite Professor Ding Ning of lymphoma Department of Peking University Cancer Hospital to give a keynote speech. Professor Ding served as the evaluation expert of National Natural Science Foundation of China, and responsible for the translational medicine cooperation research on the mechanism of ITK inhibitor combination between Angel Pharmaceuticals industry and Peking University Cancer Hospital lymphoma department.
The guests visited the R&D center of Angel Pharmaceuticals. With more than 3000 square meters, the R&D experimental center has comprehensive chemical innovative drug laboratory, biological innovative drug laboratory, experimental animal room, auxiliary room and drug analysis equipment. At the same time, the R&D center in San Francisco also launched.
Angel Pharmaceuticals will rapidly promote its own R&D to further enrich pipeline drugs. CPI-818, the world's first ITK inhibitor for T-cell lymphoma, submitted a clinical approval application to the drug examination center of the State Food and Drug Administration in July 2021. It is expected that the patients will be enrolled in this year and will join the global phase II clinical trial in the future.
